Cell-Free DNA Isolation and Extraction Market Analysis & Forecast 2031A Chapter by BIS ResearchThe global cell-free DNA isolation and extraction market was valued at $169.9 million in 2020 and is expected to reach $735.1 million by 2031, witnessing a CAGR of 14.19%The cell-free DNA testing is a non-invasive screening test that is widely applied in the field of gynecology, oncology and transplantation. It enables detection of chromosomal abnormalities in the fetus, specific mutations in cancer patients and helps to detect graft rejection. The initial steps involves the collection of patient’s sample with cell-free DNA in different forms, as required, such as fetal DNA, circulating tumor DNA and donor derived cell-free DNA based on the tests to be performed. This is followed by sequencing using various modern sequencing techniques and employing software algorithms to analyze the data to give rapid and accurate results for early disease diagnosis. The use of cell-free DNA isolation and extraction kits, tubes, and other consumables has increased due to the rising prevalence of cancer, the increasing key player initiatives, and the rising government initiatives in the cell-free DNA isolation and extraction market. The constant significant investments by healthcare companies to meet industry demand and the growing adoption of cell-free DNA isolation and extraction kits, tubes, and reagents among major end users are the major factors propelling the growth of the global cell-free DNA isolation and extraction market. The global cell-free DNA isolation and extraction market was valued at $169.9 million in 2020 and is expected to reach $735.1 million by 2031, witnessing a CAGR of 14.19% during the forecast period 2021-2031. Market Segmentation • Consumable - Cell-Free DNA Isolation and Extraction Kits, ell-Free DNA Isolation and Extraction Tubes, and Other Consumables • Platform - Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Other Platforms • Technique - Magnetic Beads-Based, Spin Column-Based, and Other Techniques • Application - Non-Invasive Prenatal Testing (NIPT), Oncology, Transplant Rejection, and Other Applications • End-User - Academic Research Institutes and Laboratories, Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Clinical Diagnostic Centers, and Other End Users. Regional Segmentation • North America - U.S., Canada • Europe - Germany, U.K., France, Italy, Spain, Denmark, and Rest-of-Europe • Asia-Pacific - China, India, Japan, Singapore, South Korea, Australia, and Rest-of-Asia-Pacific • Rest-of-the-World Competitive Landscape The global cell-free DNA isolation and extraction market comprise well-established and newly emerging companies. Several companies are attempting to sustain their position in the market by launching new products and raising funds to develop new products for the isolation and extraction of cell-free DNA from different sample types. Key market players of the global cell-free DNA isolation and extraction market witnessed product launch, product approval and business funding, and synergistic activities majorly during the period January 2018-November 2021. The inclination of companies toward product launches suggests that the companies are involved in continuously bringing new products to the market to isolate cell-free DNA, which is primarily attributed to an increase in liquid biopsy studies and approval of several liquid biopsy assays by the regulatory agencies. Market Growth Drivers • Cell-Free DNA Isolation and Extraction Inclined by Rising Prevalence of Cancer • Strategic Initiatives by Key Market Players • Rise in the Field of Microbial Sequencing
Market Challenges • High Cost of Automated Instruments • Genomic Data Protection • Rigid Regulatory Standards
Market Opportunities • Technological Advancement Toward Innovation in Cell-Free DNA Isolation and Extraction • Massive Scope for Adoption of NGS-based Genetic Tests in Emerging Markets
Key Companies Profiled Thermo Fisher Scientific Inc., QIAGEN, Danaher, PerkinElmer, Inc., Endress+Hauser AG, Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, Illumina, Inc., Takara Bio Inc., Aline Biosciences , EpiGentek Group, Inc., Omega Bio-tek, Inc., Promega Corporation, Streck, Inc., AccuBioMed Co., Ltd., AMSBIO, Covaris, Inc., EntroGen, Inc., NeoGeneStar LLC, Norgen Biotek Corp., STRATEC SE, System Biosciences, LLC, Vela Diagnostics For Custom Offerings Subscriptions - https://bisresearch.com/our-offerings/subscriptions Key Questions Answered in this Report:• How is cell-free DNA isolation and extraction revolutionizing oncology? Request a Sample - https://bisresearch.com/requestsample?id=1251type=download BIS Related Studies
© 2022 BIS Research |
Stats
73 Views
Added on April 19, 2022 Last Updated on April 19, 2022 Tags: Cell-Free DNA Isolation and Extr, Cell-Free DNA Isolation and Extr, Cell-Free DNA Isolation and Extr Author
|